Consequently, Kla may emerge as a potential target for future AD therapy; however, several questions remain to be investigated, including the exact regulators and regulatory sites of lactoylation, as well as how lactoylation dynamically changes and collaborates with other types of acylation. The gene discussed is KL; the disease is Alzheimer disease.